This study is conducted in Asia, Europe, Japan and North America. The aim of this observational study is to evaluate the safety and effectiveness while using NovoMix® 30 during 26 weeks under normal clinical practice, in the countries participating in the study. The primary outcome is the incidence of major hypoglycaemic events reported as serious adverse drugs reaction conditions on hypoglycaemic events.

Inclusion Criteria:

• Age according to approved label and physician discretion
• Type 2 diabetes including newly-diagnosed subjects who have never received insulin or an insulin analogue before

Exclusion Criteria:

• Subjects who previously enrolled in this study
• Subjects who are unlikely to comply with protocol requirements
• Hypersensitivity to biphasic insulin aspart or to any of the excipients
• Women who are pregnant, breast feeding or have the intention of becoming pregnant within next 12 months

Patients from both general and speciality practice settings who have been deemed appropriate to receive NovoMix® 30 as new treatment and as part of routine out-patient care by the prescribing physician.